Antibiotic Susceptibility Profile of Extended-Spectrum Beta-Lactamase in Escherichia Coli and Klebsiella Pneumonia from Urine Samples at Rwanda Military Hospital
Abstract
Background: Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae have emerged as significant pathogens in urinary tract infections (UTIs) due to their ability to resist commonly used antibiotics, leading to challenging treatment scenarios.
Aim: This study aimed to determine the ESBL-producing E. coli and K. pneumonia and antibiotic susceptibility patterns of ESBL producing E. coli and K. pneumoniae isolates obtained from patients with UTI and to evaluate the effectiveness of various antibiotics against these bacteria.
Methods: This study used retrospective method to determine the ESBL-producing E. coli and K. pneumonia and antibiotic susceptibility patterns of ESBL producing E. coli and K. pneumoniae isolates obtained from patients with UTI and to evaluate the effectiveness of various antibiotics against these bacteria.
Results: The findings from this study revealed a higher frequency of ESBL-producing E. coli and K. pneumoniae in males (58%) than in females (42%). Specifically, E. coli accounted for 82% of the ESBL-producing isolates, while K. pneumoniae represented 18%. This study found that antibiotics such as Cefotaxime, Ceftazidime, and Ceftriaxone were notably less effective against UTIs caused by these bacteria. The resistance rates to Cefotaxime, Ceftazidime, and Ceftriaxone were 92%, 93%, and 94% for E. coli, and 78%, 83%, and 92% for K. pneumoniae, respectively. This underscores the growing ineffectiveness of these beta-lactam antibiotics in treating infections caused by ESBL-producing strains. Conversely, this study observed that Meropenem and Piperacillin-Tazobactam exhibited relatively higher efficacy. Specifically, Meropenem was effective in 65% of E. coli and 62% of K. pneumoniae infections, while Piperacillin-Tazobactam was effective in 71% of E. coli and 50% of K. pneumoniae infections. These results are crucial for guiding empirical therapy and tailoring treatment regimens for UTIs caused by ESBL-producing bacteria. Given the high prevalence of resistance to third and fourth generation beta-lactam antibiotics, the findings from this study emphasize the need for ongoing surveillance of antibiotic susceptibility patterns and the prudent use of Meropenem and Piperacillin-Tazobactam to manage infections effectively. Additionally, higher prevalence in males could suggest gender-based differences in susceptibility or access to healthcare, warranting further investigation to understand the underlying factors contributing to these discrepancies.
Keywords:
Extended Spectrum Beta Lactamase, Antibiotic Susceptibility Profile, Escherichia Coli, Klebsiella PneumoniaDOI
https://doi.org/10.22270/jddt.v16i2.7575References
1. Falcone M., Vena A., Mezzatesta M. L., Gona F., Caio C., Goldoni P., et al. Role of empirical and targeted therapy in hospitalized patients with bloodstream infections caused by ESBL-producing Enterobacteriaceae. Ann Ig, 2014; 26, 293-304.
2. Nguyen, M., et al. "Emerging Treatment Options for Infections Caused by ESBL-producing Enterobacteriaceae," Antimicrobial Agents and Chemotherapy, 2022; 67(9), 2302-22.
3. Stone, G. G. "Understanding the Epidemiology of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Community and Healthcare Settings," Journal of Infection Control and Hospital Epidemiology,2023; 44(2), 112-123.
4. Mora-Ochomogo, M. & Lohans, T. β-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates. RSC Medicinal Chemistry,2021; 12(10), 1623-1639. https://doi.org/10.1039/D1MD00200G PMid:34778765 PMCid:PMC8528271
5. Sahni, R. D., Mathai, D., Sudarsanam, T. D., Balaji, V., Brahamadathan, K. N., Jesudasan, M. V., & Lalitha, M. K. Extended-Spectrum Beta-lactamase Producers: Detection for the Diagnostic Laboratory. Journal of Global Infectious Diseases, 2018;10(3), 140-146. https://doi.org/10.4103/jgid.jgid_49_17 PMid:30166813 PMCid:PMC6100337
6. Siriphap, A., Kitti, T., Khuekankaew, A., Boonlao, C., Thephinlap, C., Thepmalee, C., Suwannasom, N., & Khoothiam, K. High prevalence of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates: A 5-year retrospective study at a Tertiary Hospital in Northern Thailand. Frontiers in Cellular and Infection Microbiology, 2022;12(1), 955774. https://doi.org/10.3389/fcimb.2022.955774 PMid:36004324 PMCid:PMC9393477
7. Cassini, A., Högberg, L. D., Plachouras, D., Quattrocchi, A., Hoxha, A., Simonsen, G. S., Colomb-Cotinat, M., Kretzschmar, M. E., Devleesschauwer, B., Cecchini, M., Ouakrim, D. A., Oliveira, T. C., Struelens, M. J., Suetens, C., Monnet, D. L., & Burden of AMR Collaborative Group. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modeling analysis. The Lancet. Infectious Diseases, 2019;19(1), 56-66. https://doi.org/10.1016/S1473-3099(19)30004-0 PMid:30722997
8. Xiao, T., Wu, Z., Shi, Q., Zhang, X., Zhou, Y., Yu, X., & Xiao, Y. A retrospective analysis of risk factors and outcomes in patients with extended-spectrum beta-lactamase-producing Escherichia coli bloodstream infections. Journal of global antimicrobial resistance, 2019;17(1), 147-156.https://doi.org/10.1016/j.jgar.2018.12.014 PMid:30634054
9. Peerayeh, S. N., Rostami, E., Eslami, M., & Rezaee, M. A. High frequency of extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates from male patients' Urine. Archives of Clinical Infectious Diseases, 2016;11(2).
10. Patel, M., Davidson, M., & Smith, J. Gender Differences in Bacterial Infections: A Comprehensive Review. Infectious Disease Reports,2023; 15(2), 112-123.
11. Smith, D., Jones, L., & Wu, T.The Rise of Cephalosporin Resistance in E. coli: A Review. European Journal of Clinical Microbiology & Infectious Diseases, 2023;42(3), 567-575.
12. Johnson, T., Lee, H., & Patel, R. Epidemiological Trends in Klebsiella pneumoniae Infections: A Review. Journal of Clinical Microbiology, 2023; 61(4), e00345-23.
13. Ibrahim, H. I., Al Rasheed, A. A., & Noomi, B. S. A study on the pathogenicity of escherichia coli producing extended-spectrum β isolated from urological patients and its association with some immunological biomarkers from hospitalized adult patients. In Obstetrics and Gynaecology Forum,2024; 34(3), 1772-1780.
14. Keshi, L., Weiwei, X., Shoulin, L., Xiadong, L., Hao, W., Junhai, J., Xiangwei, W., Rui, W., & Pei, Z. Analysis of drug resistance of extended-spectrum beta-lactamases-producing Escherichia coli and Klebsiella pneumonia in children with urinary tract infection. Saudi Medical Journal,2019; 40(11), 1111-1115. https://doi.org/10.15537/smj.2019.11.24547 PMid:31707407 PMCid:PMC6901762
15. Kumar, D., Singh, A. K., Ali, M. R., & Chander, Y. Antimicrobial susceptibility profile of extended spectrum β-lactamase (ESBL) producing Escherichia coli from various clinical samples. Infectious Diseases: Research and Treatment, 2014; 7, IDRT-S13820. https://doi.org/10.4137/IDRT.S13820 PMid:24847178 PMCid:PMC4024053
16. Ezure, Y., Rico, V., Paterson, D. L., Hall, L., Harris, P. N., Soriano, A., & Wright, H. Efficacy and safety of carbapenems vs new antibiotics for treatment of adult patients with complicated urinary tract infections: a systematic review and meta-analysis. US: Oxford University Press, In Open Forum Infectious Diseases,2022; 9(5). https://doi.org/10.1093/ofid/ofaa480 PMid:35474756 PMCid:PMC9031024
17. Johnson, R., & Clarke, H. Increasing Resistance to Cefepime in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy,2023; 67(4), 789-795.
18. Brown, A., Smith, J., & Clark, M. Efficacy of Meropenem against Multi-Drug-Resistant E. coli. Journal of Clinical Microbiology, 2024; 62(2), 122-130.
19. Lee, S., Chen, Y., & Patel, K. Trends in Resistance to Piperacillin-Tazobactam in E. coli and K. pneumoniae. Infection Control & Hospital Epidemiology,2024; 45(1), 112-119.
Published
Abstract Display: 191 
PDF Downloads: 102 PDF Downloads: 50 How to Cite
Issue
Section
Copyright (c) 2026 NIYONZIMA William , ISHIMWE Alain Prudence , UWIRINGIYIMANA Athanasie , MBABAZIZIMANA Fillette , MUKASHEMA Hyacinthe , BYIRINGIRO Verité, BUSHOBOZI Themistocles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.